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Plasma levels, protein binding, and elimination data 
of lidocaine and active metabolites in cardiac patients 
of various ages 
The serum and urine levels qf lidocaine and two active dealkyluted metabolites, 
monoethylglycinexylidide (MEGX) and glycinexylidide (GX), were determined by HPLC in 33 
cardiac patients receiving lidocaine,for more than I day. Clinical assessment of nervous system 
toxicity was carried out at the time of blood drawing. The ratios in serum of MEGX to lidocaine 
and of GX to lidocaine were 0.36 & 0.26 (mean + SD) and 0.11 2 0.11. Lidocaine and MEGX 
binding to serum proteins from seven patients 2 days after their myocardial infarctions were 
55.4 + 5.9% and 14.3 + 3.0%. After correction for this diflerence in protein binding, the 
MEGXllidocaine ratio in serum water was 0.68 & 0.49. MEGX levels in serum water were 80% 
or more of the lidocaine levels in I1 of the 33 patients. GX binding was 5 & 4%. Even after 
correction for protein-binding differences, GX levels in serum water were low compared to 
lidocaine levels. The steady-state serum GX concentration normalized for lidocaine infusion rate 
declined with age. Of 27 patients without toxicity, six had serum lidocaine levels above 8 
pglml. Five of six patients with toxicity had levels less than 8 pglml. The renal clearance of 
lidocaine, MEGX, and GX was less than creatinine clearance in most patients. We conclude 
that MEGX, but not GX,  contributes to the pharmacologic activity of lidocaine therapy in a 
substantial fraction of patients. We also suggest that the concept of a single value for the upper 
limit of the therapeutic level of lidocaine in serum is an oversimplijication because it does not 
take into account individual d~fferences in drug-protein binding or accumulation of active 
metabolites. 
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Lidocaine is eliminated mainly by biotransfor- (about 3% of a dose in man). The major pathway 
mation to monoethylglycinexylidide (MEGX); a of elimination of MEGX is biotransformation to 
small amount is excreted unchanged in the urine 2,6-xylidine and, to a much lesser extent, to 
glycinexylidide (GX). The major lidocaine uri- 
nary metabolites in man are coniugates of 4- 
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Fig. 1. Chemical structures for lidocaine and metabolites in man. Chemical structures for other 
metabolites (minor) are presented in Collinsworth et a1.6 
is about half as potent in vivo in dogs.22 MEGX 
also has local anesthetic activity6 and convul- 
sant activity in animals.', In fact, the convul- 
sant activity of lidocaine and MEGX seem ad- 
d i t i ~ e . ~  Although the pharmacologic activity of 
MEGX in man has not been confirmed, the 
paresthesia and confusion in a patient of Halkin 
et al.'%n lidocaine were most likely due to 
MEGX, since the patient's lidoraine level of 
3.5 pglml was within the accepted therapeutic 
range but the metabolite level of 4.2 pglml was 
higher than that of the parent drug. 
In contrast, the antiarrhythrnic activity of GX 
in mice was much less than that of l i d o ~ a i n e , ~ ~  
and this was also seen in vitro in a guinea pig 
atrium model.4 GX also seemed to potentiate 
the convulsant activity of MEGX and lidocaine 
in rats2 and itself had CNS depressant activity in 
these animals. When GX was infused into two 
normal subjects to achieve levels as high as, or 
higher than, those seen clinically after lido- 
caine, none of the major toxic effects associated 
with lidocaine therapy were ~bserved. '~ GX, 
however, did induce headache and adversely af- 
fected mental performance in these subjects. 
GX and MEGX also have the ability to constrict 
vascular smooth muscle . I 0  
Our purpose is to provide serum level and 
elimination data for lidocaine, MEGX, and GX 
in cardiac patients of various ages. We also 
interpret the contribution of MEGX and GX to 
the pharmacologic activity of lidocaine after 
serum protein binding is taken into account. 
Materials and methods 
Our subjects were 33 patients in The New 
York Hospital Coronary Care Unit who were 
receiving lidocaine infusions at rates prescribed 
by their physicians for treatment of arrhyth- 
mias. For inclusion in the study, patients must 
have been receiving lidocaine for more than 24 
hr. Patients were assessed for manifestations of 
lidocaine toxicity, including muscle twitching, 
paresthesias, dysarthria, drowsiness, disorien- 
tation, and seizures at the time blood was drawn 
for assays. Blood was collected in a syringe and 
allowed to clot in a glass test tube. Contact with 
stoppers was avoided. The patients' charts were 
subsequently reviewed for diagnosis, concur- 
rent drug therapy, clinical laboratory values, 
and clinical course. In each patient with man- 
ifestations of lidocaine toxicity the manifesta- 
tions subsided after dosage reduction or with- 
drawal of lidocaine. 
Six patients were considered to have lido- 
caine toxicity, and these were compared to the 
27 who did not have toxicity. The following 
variables were considered: age; creatinine clear- 
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Table I .  Patient data and steady-state serum level data for GX, MEGX, and lidocaine 
in cardiac patients receiving lidocaine 
- 
1 F 61 66.2 
2 M 74 80.6 
3$ M 60 82.0 
4 M 59 87.8 
5 M 76 77.8 
6 F 80 68.0 
7 M 5 8 80.5 
8 F 77 54.0 
9 M 66 73.6 
10 M 86 78.4 
1 I$ M 70 68.0 
12 M 68 83.3 
13 M 55 60.0 
14 M 5 8 76.3 
15 F 49 59.6 
164 M 8 1 72.1 
17 F 5 1 75.4 
18 M 66 78.1 
19 M 72 77.1 
20$ M 57 92.4 
2 1 F 7 1 61.8 
22 M 65 81 .5 
23 M 6 1 81.9 
24 F 77 56.8 
Mean * SD 67 ? 10 
*Patient had congestive hean failure. The level from this patient was excluded from all analysis. 
?Patient was receiving propranolol. 
SLidocaine toxicity was suspected. Two other patients (lidocaine, 6 pg/ml, and MEGX, 2.5 pg/ml; lidocaine, 4.1 pg/ml, and MEGX, 4 
pg/ml) were suspected of lidocaine toxicity. They are not included in this table because the lidocaine levels were not at presumed steady state. 
$This concentration was below the detectability of the method. 
I1Values from patients 9, 12, and 24 were excluded fmm analysis. 
?Patient was receiving metoprolol 
Patient No. 
Serum concentration 





ance; serum bilirubin; SGOT; and serum lido- 
caine, MEGX, and GX levels. Of the 33 pa- 
tients, 21 were presumed to be at steady state 
for lidocaine (infusion rate constant for the 12 
hr before evaluation). Serum samples from 
these subjects were used for the kinetic studies 
(Table I). Most of these patients were also re- 
ceiving propranolol or other P-adrenergic- 
blocking drugs. Propranolol, and probably other 
P-adrenergic-blocking drugs as well, reduces 
lidocaine clearance. l8 Most patients had a recent 




subjects with congestive heart failure are also 
presented in Table I, but they were not included 
in the analysis of the data because this disorder is 
known to decrease the clearance of l i d o ~ a i n e . ~ ~  
Lidocaine, MEGX, and GX (supplied by 
Astra) were measured in serum or urine as fol- 
lows: To a 16 x 25 mm Teflon-capped glass 
extraction tube, add 1 ml of serum or diluted 
urine, 100 p1 of a 20-pglml aqueous solution of 
the internal standard (the primary amine of 
etidocaine [also supplied by Astra]), 200 p1 of 
5N NaOH, and 200 p1 of a saturated NaCl so- 
Age 
( ~ r )  
MEGX 
1 )  
Lidocaine 
( p g w  
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bilirubin I SCOT (mg /dl) (unitsll) 
lution. Mix by vortexing briefly. Add 3 ml arnyl 
acetate, cap, and rotate on a mechanical rotator 
(Model 15 1; Scientific Industries) at approxi- 
mately 14 rpm for 30 min. Centrifuge (4000 
rpm, 5 min) and transfer the organic phase to 
a new Concentratube (Laboratory Research). 
While vortexing, add 100 p1 of O.1N H2S04; 
continue vortexing vigorously for 30 sec. Cen- 
trifuge and inject 10 p1 of the acid phase into 
the liquid chromatograph. 
We used a Waters HPLC equipped with a 
Model M6000A solvent delivery system, a 
U-6K injector, a reverse-phase column (mi- 
cro-BondapakIPhenyl, Waters), a Model 450 
variable-wavelength UV detector (Waters) set 
at 200 nm, and a Varian A25 chart recorder. 
The mobile phase was Burdick and Jackson 
acetonitrile in phosphoric acid (0.5 ml in 1 1 
water, which is then adjusted to pH 2.8 with 
50% [wlw] NaOH) as a 10: 90 mixture by vol- 
ume. At the end of each workday, the system is 
flushed by pumping 20% acetonitrile in water at 
a flow rate of 2 mllmin for 20 min. We have 
used this system for 6 mo with no problems. At 
a flow rate of 2 mllmin, the retention times 
for GX, MEGX, the internal standard, and li- 
docaine are 5.8, 7.8, 9.5, and 11.5 min, re- 
spectively. A linear relationship between peak 
height ratios (peak height of compound to peak 
of the internal standard) and concentration was 
as follows: 0.1 to at least 4 pglml for GX, 0.25 
to at least 8 pglml for MEGX, and 0.5 pglml 
to at least 16 pglml for lidocaine. A standard 
curve for GX, MEGX, and lidocaine from 
either serum or water was always determined 
concurrently with patient samples. 
The coefficient of variation (CV) of the assay 
for GX, MEGX, and lidocaine, obtained from 
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Table 11. Serum level dam for 33 cardiac patients receiving lidocaine, strat@ed by 
Nontoxic 27 67 + lo* 6.0 ? 3.3t 1.9 i 1.311 0.45 + 0.44 
(5 1 -86)$ (2.2-16.5) (0.3-5.2) (0.05-1.4) 
Toxic 6 68 2 10 6.2 t 1.35 2.6 + 0.811 0.46 +- 0.33 
(57-81) (4.1-8.3) (1.5-4.0) (0.20-1.1) 
presence or absence of toxicity 
*Mean ? SD. 
tSix subjects had lidocaine levels greater than 8 wg/ml without toxicity. 
$Range. 
$Five subjects had lidocaine levels below 8 pg /ml  with toxicity. 
//P < 0.05 by Wilcoxon's rank order test (one-tailed) compared to nontoxic levels. 
analysis of six replicate samples from a serum 
pool containinq 0.5 pglml GX, 1 pglml 
MEGX, and 2.0 pglml lidocaine, was 4%, 2%, 
and 2%. The CV of this method, obtained from 
daily analysis (N = 8) over 4 mo, was 7% for 
GX, 7% for MEGX, and 7% for lidocaine for 
our low standard containing 0.25 pglml GX, 
0.5 pglml MEGX, and 1 pglml lidocaine. 
The ratio of GX, MEGX, and lidocaine 
clearance to endogenous creatinine clearance 
was calculated from a single voided urine spec- 
imen and a simultaneously drawn blood sample. 
The ratio equals drug concentration in urine 
times serum creatinine concentration divided 
by the product of urine creatinine concentra- 
tion and drug concentration in serum. Serum 
creatinine was measured by Auto-Analyzer and 
urine creatinine by the traditional alkaline pic- 
rate method with spectrophotometry. Lidocaine 
clearance (ml/min/kg) was calculated for each 
patient as follows: Lidocaine clearance = Li- 
docaine infusion ratellidocaine serum level at 
presumed steady state. Creatinine clearance for 
each male subject was calculated from the fol- 
lowing equation": 
[I40 - age (yr)] X weight in kg 
72 X serum creatinine (mg/dl) 
Age 
fyr)  Type 
Concentration (pglrnl) 
For women, this ratio is multiplied by 0.85. 
The binding of lidocaine, MEGX, and GX 
was determined in serum drawn from five nor- 
mal subjects and from seven patients 2 days 
after myocardial infarction. The blood was 
drawn into glass syringes and allowed to clot in 
15-ml glass test tubes. Serum from the normal 
No. of 
putienrs Lirlocaine 
subjects was used immediately, whereas that 
from most of the patients was stored in a frozen 
state before being used. Aliquots of serum were 
placed in dialysis tubing (Fisher Scientific). The 
dialysis tubing was then placed for 24 hr in pH 
7.4 phosphate buffer (0.05M) at room tempera- 
ture containing either 0.5 pglml GX, 2 pglml 
MEGX, or 2 pglml lidocaine. The samples 
were then analyzed by HPLC, and the ratio of 
the drug concentration in buffer to the concen- 
tration in dialyzed serum was considered the 
unbound fraction. 
GX, MEGX, and lidocaine were added to 
heparinized whole blood from three subjects to 
give concentrations of 0.5, 1, and 2 pglml. 
Half of each subject's blood was added to red- 
stoppered Vacutainers (Becton, Dickenson). 
These tubes were inverted 10 times, left on their 
side at room temperature for 30 min, and stored 
on their side in the refrigerator overnight. The 
other half of each subject's blood was placed in 
glass tubes and immediately stored upright in 
the refrigerator. The samples were then ana- 
lyzed and compared. 
Aliquots of standards containing 20 pglml 
GX, 20 pglml MEGX, and 20 pglml lidocaine 
in pH 7.4 phosphate buffer (0.05M) were vor- 
texed with equal volumes of 1-octanol. An 
aliquot of the original aqueous solution and an 
aliquot of the buffer after the octanol mixing 
were then analyzed by HPLC. The partition 
coefficient equals the concentration in 1-octanol 
divided by the concentration in buffer. The con- 
centration of the compound in the organic phase 
is equal to the difference in concentration of the 
MEGX G X  
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AGE ( Y E A R S )  
Fig. 2. Effect of age on steady-state MEGX serum 
levels normalized for lidocaine infusion rate. Solid 
circles are MEGX levels from the three outliers in 
Fig. 4. 
compound in the aqueous buffer before and 
after 1-octanol extraction. 
The linear regression equation was calculated 
by the least-squares technique. The t test to 
show significant deviation of the correlation 
coefficient from zero was by the method of 
Swinscow .25 
Results 
The serum level data for lidocaine, MEGX, 
and GX in 27 nontoxic patients and six toxic 
patients are listed in Table 11. The serum 
MEGXIlidocaine and GXIlidocaine ratios aver- 
aged 0.36 + 0.26 and 0.11 + 0.11. Twenty- 
four of these patients were presumed to be at 
steady state for lidocaine levels. Patient infor- 
mation, steady-state levels of lidocaine, MEGX, 
and GX, and lidocaine clearance values in these 
patients are presented in Table I. The ages of 
the patients averaged 67 + 10 yr (range, 49 to 
86). In these patients at presumed steady state, 
MEGX serum levels averaged 31% that of 
lidocaine, whereas GX levels were much lower, 
averaging only 7.5% that of the parent drug. 
Age had no effect on the presumed steady- 
state serum MEGX levels normalized for lido- 
caine infusion rate (Fig. 2) or normalized for 
lidocaine serum level. Serum MEGX (pg/ml)/ 
A G E  ( Y E A R S )  
Fig. 3. Effect of age on steady state GX serum levels 
normalized for lidocaine infusion rate. Solid circles 
are GX levels from the three outliers in Fig. 4. 
lidocaine infusion rate (mglkglmin) = 65.4 - 
0.17peryearofage(r = -0.05,N = 21). The 
steady-state serum GX concentration normal- 
ized for lidocaine infusion rate declined with 
age (Fig. 3). Serum GX (pg/ml)/lidocaine in- 
fusion rate (mglkgl min) = 48.13 - 0.49 per 
year of age, but this correlation is not strong 
(r = -0.39, P 0.1, N = 19). The correlation 
with age is even weaker when serum GX levels 
are normalized for lidocaine serum levels 
(r = -0.17). 
We have observed that in 6 of 27 subjects 
without toxicity, lidocaine levels were above 8 
pglml. In one of these patients the lidocaine 
level was 16.5 pglml (MEGX, 0.77 pglml, 
and GX, less than 0.1 pglrnl) in serum from 
blood drawn 0.5 hr after the end of a 34-hr 
lidocaine infusion. In five of the six subjects 
with toxicity, lidocaine levels were below 8 
pglml. In fact, the only difference between the 
toxic and the nontoxic patients in this study 
(Table 11) was that on the average the toxic pa- 
tients had higher MEGX levels. In the two 
groups, age, renal function (as determined by 
creatinine clearances), and liver function (as de- 
termined by serum bilirubin and SGOT) did not 
differ substantially. 
The effect of age on lidocaine clearance is 
presented in Fig. 4. The lidocaine clearance 
averaged 5.8 + 1.5 (SD) ml/min/kg and de- 
clined with age if the three very high lidocaine 
20 Drayer et al. Clin. Pharmacol. Ther. July 1983 
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Fig. 4. Effect of age on lidocaine clearance. Three 
outliers (solid circles) were excluded from analysis. 
values from patients 9, 12, and 24 are excluded. 
(These patients clearly represent a different pa- 
tient population, since their values were more 
than 3 SD above the mean.) The equation of the 
best fit line by least-squares linear regression is 
as follows: Lidocaine clearance (mllminlkg) = 
9.7 - 0.06 per year of age (r = -0.42, 
P < 0.05, N = 18). This clearance was, how- 
ever, independent of creatinine clearance in 15 
of the 18 subjects (in the other three, serum 
creatinine levels and therefore creatinine clear- 
ances could not be determined because of 
hemolysis). The ratio of GX renal clearance to 
creatinine clearance averaged 0.60 + 0.41 
(range, 0.14 to 1.7). In only 4 of the 22 subjects 
was this ratio above 1.0. The ratio of MEGX 
renal clearance to creatinine clearance averaged 
0.72 + 0.48 (range, 0.08 to 2.19). In only 4of 
the 22 subjects was this ratio above 1.0. The 
ratio of lidocaine renal clearance to creatinine 
clearance averaged 0.23 + 0.27 (range, 0.02 
to 1.17). In only 1 of the 20 patients was this 
ratio above 1 .O. The lidocaine renal clearance 
averaged 3.2 -+ 1.8% of the total clearance 
(N = 19). 
The protein binding of lidocaine, MEGX, 
and GX in serum (at room temperature) from 
five normal subjects averaged 50 + 9% 
(mean + SD), 15 + 3%, and 5 + 4%. The 
binding of lidocaine and MEGX to serum pro- 
teins drawn from seven patients 2 days after 
their myocardial infarctions averaged 55 + 6% 
and 14 + 3.0%. Thus percent unbound in pa- 
tients' serum water was 45% for lidocaine and 
86% for MEGX. Since GX binding was only 
5% and its total level was so low, it was con- 
sidered inconsequential and was not studied 
further. 
Heparinized blood stored in red-stoppered 
Vacutainers had no effect on GX and MEGX 
plasma concentration levels, but exposure of 
lidocaine to the stopper lowered the lidocaine 
concentration level in plasma by 20%. 
The octanollbuffer (pH = 7.4) partition co- 
efficient (K,) was 65.0 for lidocaine, 5.7 for 
MEGX, and 1.3 for GX. 
Discussion 
The individual ratios of serum levels of 
MEGX to lidocaine and of GX to lidocaine in 
the 33 cardiac patients averaged 0.36 + 0.26 
and 0.11 + 0.11. These ratios are of the same 
order as those in the literature.', 12, l6 The in- 
tensity of a drug's action is related to its con- 
centration in plasma water, since this estab- 
lishes the diffusion gradient for the drug to get 
to the receptor site. The correction factor for 
converting the total MEGXIlidocaine ratio in 
serum to that in serum water equals 86%/45%, 
or 1.9 (protein-binding data from seven patients 
with a myocardial infarction 2 days before anal- 
ysis), and therefore the MEGXIlidocaine ratio 
in serum water averages 0.68 k 0.49. In fact, 
MEGX levels in serum water were at least 80% 
or more than those of lidocaine in 11 of the 33 
patients. Assuming that MEGX is 0.5 to 1 times 
as potent as lidocaine for antiarrythmic and toxic 
effects (since this was the potency observed in 
animals), then MEGX contributes to the phar- 
macologic activity of lidocaine therapy in a sub- 
stantial proportion of lidocaine-treated patients. 
The protein binding of lidocaine is known to 
be increased in several clinical situations, such 
as recent myocardial infarctionlS~ (applies to 
most of our patients), increasing age, chronic 
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renal failure, epilepsy (treated), malignancy (re- 
viewed in Routledge et al."), and t r a ~ m a . ~  The 
increased lidocaine protein-binding is thought 
to be due to the rise of a,-acid glycoprotein in 
plasma, which can increase for 5 to 7 days after 
these events and can remain elevated for as long 
as 2 to 3 ~ k . ~ ,  l4  This implies that the ratio of 
MEGX to lidocaine in plasma water may be 
above 0.68 if the patient receiving the lidocaine 
has a marked increase in levels of this binding 
protein after myocardial infarction. 
Because of the low plasma levels of GX rela- 
tive to lidocaine, even after correction for 
protein-binding differences and the low potency 
of GX in experimental studies relative to 
lidocaine, we believe that GX contributes very 
little to the pharmacologic effects of lidocaine. 
There is no effect of age on the steady-state 
MEGX plasma level normalized for lidocaine 
infusion rate (Fig. 2). This conclusion is also 
reached if one plots the data of Halkin et al. , I 2  
but the steady-state GX plasma level nor- 
malized for lidocaine dose decreases with age 
(Fig. 3). This was unexpected, since GX is 
eliminated 50% unchanged in the urine,24 and 
renal function, as measured by endogenous 
creatinine clearance, decreases in elderly per- 
sons.8 This decrease in normalized GX plasma 
levels in elderly persons may be explained by 
proposing that GX formation from MEGX is 
decreased in elderly persons to a greater extent 
than aging slows the elimination of GX into 
urine. 
Davison et al.7 reported that in only 88 of 362 
blood samples drawn from patients with sus- 
pected lidocaine toxicity was the lidocaine level 
above 5 pglml. The remainder of patients ap- 
parently had lidocaine levels below this value. 
Some of the toxic patients had elevated MEGX 
levels. Lidocaine levels in nontoxic patients 
were not measured. Buckman et al.3 report that 
20 of 44 patients who had lidocaine levels below 
6 pglml had toxicity, and all six patients with 
higher lidocaine levels had toxicity. Lidocaine 
plasma levels associated with serious toxicity 
have also been reported to be above 8 pglml." 
Of our 27 subjects without toxicity, six had 
serum lidocaine concentrations above 8 pglml. 
We also observed that five of six subjects with 
toxicity had lidocaine levels below 8 pglml. In 
fact, the only difference we observed between 
the toxic aid nontoxic patients in our study 
(Table 11) was that, on the average, the toxic 
patients had higher MEGX levels. The implica- 
tion is that MEGX contributes to toxicity during 
lidocaine therapy. We therefore suggest that the 
concept of a single value for the upper limit of the 
therapeutic range for serum lidocaine concentra- 
tion is an oversimplification because it does not 
take into account individual difference in protein 
binding of the parent drug or active metabolite 
accumulation. 
Three elderly subjects (ages above 65 yr) 
had very rapid lidocaine clearance values and 
clearly represented a different patient population 
from the remainder of the elderly subjects. Re- 
view of the charts of these patients gave no 
reason for their high clearance values. In a 
much smaller study, Nation et al." observed 
one elderly subject who had a lidocaine clear- 
ance value that was more than 2 SD above the 
mean of the values of the other elderly subjects. 
The ratio of lidocaine, MEGX, and GX renal 
clearance to creatinine clearance is below 1.0 
for most of our patients, indicating that net renal 
tubular secretion of these compounds does not 
occur. However, the high lipid solubility of 
lidocaine and MEGX (K, substantially above 
1.0), and to a lesser extent of GX (K, = 1.3), 
permits diffusion of these compounds from the 
urine in the renal tubules back into the blood. 
This may mask any renal tubular secretion of 
these basic compounds into the urine. 
Lidocaine is more lipophilic (highest K,) 
than its two metabolites, MEGX and GX, and is 
50% bound to plasma proteins in normal sub- 
jects. GX is the least lipophilic (lowest K,) of 
these three compounds and is only 5% bound to 
plasma proteins. MEGX is of intermediate po- 
larity and protein binding. 
Several years ago Stargel et reported that 
collecting blood in red-stoppered Vacutainer 
tubes caused about a 28% reduction in lidocaine 
serum levels. We confirmed this; it still is a 
problem. It has been proposed that the chemical 
tris(2-butoxyethyl)phosphate, which is present 
in the rubber stopper, is leached out and dis- 
places this basic drug from its serum protein 
binding sites. The drug then redistributes into 
the erythrocytes, producing spuriously low 
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